Wall Street Experts
ver. ZuMIgo(08/25)
Sutro Biopharma, Inc.
Rachunek Zysków i Strat
Przychody TTM (mln): 161
EBIT TTM (mln): -89
| index |
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
| Rok finansowy |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
| Przychód (mln) |
60 |
52 |
38 |
43 |
43 |
62 |
68 |
154 |
62 |
| Przychód Δ r/r |
0.0% |
-13.4% |
-25.7% |
11.2% |
-0.0% |
44.8% |
9.5% |
126.8% |
-59.6% |
| Marża brutto |
100.0% |
100.0% |
100.0% |
-53.5% |
-80.1% |
84.2% |
87.8% |
95.6% |
100.0% |
| EBIT (mln) |
1 |
-19 |
-37 |
-55 |
-71 |
-99 |
-129 |
-89 |
-238 |
| EBIT Δ r/r |
0.0% |
-1512.9% |
93.1% |
49.0% |
28.1% |
38.7% |
30.9% |
-30.8% |
167.1% |
| EBIT (%) |
2.3% |
-37.2% |
-96.9% |
-129.8% |
-166.3% |
-159.2% |
-190.3% |
-58.1% |
-384.3% |
| Koszty finansowe (mln) |
0 |
1 |
2 |
4 |
4 |
3 |
3 |
24 |
31 |
| EBITDA (mln) |
7 |
-14 |
-29 |
-47 |
-65 |
-93 |
-125 |
-82 |
-187 |
| EBITDA(%) |
12.3% |
-27.2% |
-75.9% |
-109.1% |
-152.7% |
-150.5% |
-185.2% |
-53.6% |
-301.1% |
| Podatek (mln) |
0 |
1 |
4 |
0 |
4 |
3 |
2 |
18 |
2 |
| Zysk Netto (mln) |
2 |
-20 |
-35 |
-56 |
-36 |
-109 |
-119 |
-107 |
-227 |
| Zysk netto Δ r/r |
0.0% |
-1256.8% |
79.4% |
57.8% |
-35.1% |
200.2% |
9.7% |
-10.4% |
113.0% |
| Zysk netto (%) |
2.8% |
-38.1% |
-91.9% |
-130.4% |
-84.7% |
-175.6% |
-175.9% |
-69.5% |
-366.6% |
| EPS |
0.24 |
-2.81 |
-6.13 |
-2.43 |
-1.11 |
-2.36 |
-2.35 |
-1.78 |
-2.96 |
| EPS (rozwodnione) |
0.24 |
-2.81 |
-6.13 |
-2.43 |
-1.11 |
-2.36 |
-2.35 |
-1.78 |
-2.96 |
| Ilośc akcji (mln) |
7 |
7 |
6 |
23 |
33 |
46 |
51 |
60 |
77 |
| Ważona ilośc akcji (mln) |
7 |
7 |
6 |
23 |
33 |
46 |
51 |
60 |
77 |
| Waluta |
USD |
USD |
USD |
USD |
USD |
USD |
USD |
USD |
USD |